Annexin Pharmaceuticals AB (publ) (ANNX.ST)
SEK 0.31
(14.34%)
SEK 0.31
(14.34%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 7.94 Million SEK | 21.81% |
| 2022 | 6.52 Million SEK | 7.71% |
| 2021 | 6.05 Million SEK | 34.05% |
| 2020 | 4.52 Million SEK | -0.59% |
| 2019 | 4.54 Million SEK | -26.52% |
| 2018 | 6.18 Million SEK | -3.45% |
| 2017 | 6.4 Million SEK | -18.72% |
| 2016 | 7.88 Million SEK | 140.18% |
| 2015 | 3.28 Million SEK | 234.61% |
| 2014 | 981.13 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 5.46 Million SEK | -31.24% |
| 2024 Q2 | 5.36 Million SEK | -1.79% |
| 2024 Q3 | 3.51 Million SEK | -34.58% |
| 2023 Q2 | 11.52 Million SEK | 162.24% |
| 2023 Q1 | 4.39 Million SEK | -32.64% |
| 2023 FY | 7.94 Million SEK | 21.81% |
| 2023 Q4 | 7.94 Million SEK | -48.21% |
| 2023 Q3 | 15.35 Million SEK | 33.15% |
| 2022 FY | 6.52 Million SEK | 7.71% |
| 2022 Q4 | 6.52 Million SEK | 2.56% |
| 2022 Q3 | 6.36 Million SEK | 17.66% |
| 2022 Q2 | 5.4 Million SEK | -2.26% |
| 2022 Q1 | 5.53 Million SEK | -8.68% |
| 2021 Q4 | 6.05 Million SEK | 37.11% |
| 2021 Q1 | 8.57 Million SEK | 89.69% |
| 2021 Q2 | 4.4 Million SEK | -48.61% |
| 2021 FY | 6.05 Million SEK | 34.05% |
| 2021 Q3 | 4.41 Million SEK | 0.3% |
| 2020 Q2 | 3.83 Million SEK | -42.29% |
| 2020 Q1 | 6.65 Million SEK | 46.25% |
| 2020 Q3 | 2.83 Million SEK | -26.08% |
| 2020 Q4 | 4.52 Million SEK | 59.32% |
| 2020 FY | 4.52 Million SEK | -0.59% |
| 2019 Q3 | 4.94 Million SEK | 37.32% |
| 2019 Q1 | 3.9 Million SEK | -36.96% |
| 2019 FY | 4.54 Million SEK | -26.52% |
| 2019 Q4 | 4.54 Million SEK | -8.05% |
| 2019 Q2 | 3.6 Million SEK | -7.69% |
| 2018 Q1 | 7.17 Million SEK | 11.91% |
| 2018 FY | 6.18 Million SEK | -3.45% |
| 2018 Q4 | 6.18 Million SEK | 43.61% |
| 2018 Q3 | 4.3 Million SEK | -37.4% |
| 2018 Q2 | 6.88 Million SEK | -4.03% |
| 2017 Q3 | 9.22 Million SEK | -14.51% |
| 2017 Q4 | 6.4 Million SEK | -30.56% |
| 2017 FY | 6.4 Million SEK | -18.72% |
| 2017 Q1 | 17.22 Million SEK | 118.48% |
| 2017 Q2 | 10.79 Million SEK | -37.33% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q4 | 7.88 Million SEK | 0.0% |
| 2016 FY | 7.88 Million SEK | 140.18% |
| 2015 FY | 3.28 Million SEK | 234.61% |
| 2014 FY | 981.13 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alzinova AB (publ) | 9.33 Million SEK | 14.811% |
| Amniotics AB (publ) | 10.54 Million SEK | 24.633% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -79.598% |
| BioArctic AB (publ) | 139.5 Million SEK | 94.302% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.492% |
| Genovis AB (publ.) | 98.04 Million SEK | 91.893% |
| LIDDS AB (publ) | 3.75 Million SEK | -111.635% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 93.588% |
| OncoZenge AB (publ) | 1.69 Million SEK | -367.863% |
| Saniona AB (publ) | 86.08 Million SEK | 90.766% |
| Simris Alg AB (publ) | 148.93 Million SEK | 94.663% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 80.545% |
| AcouSort AB (publ) | 10.37 Million SEK | 23.405% |
| Active Biotech AB (publ) | 13.4 Million SEK | 40.679% |
| Camurus AB (publ) | 414.81 Million SEK | 98.084% |
| Cantargia AB (publ) | 54.97 Million SEK | 85.539% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -107.113% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 57.018% |
| Mendus AB (publ) | 51.22 Million SEK | 84.482% |
| Kancera AB (publ) | 17.97 Million SEK | 55.785% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 31.291% |
| Lipum AB (publ) | 7.53 Million SEK | -5.452% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -54.11% |
| NextCell Pharma AB | 13.68 Million SEK | 41.932% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 98.351% |
| Xintela AB (publ) | 14.01 Million SEK | 43.282% |
| Ziccum AB (publ) | 6.38 Million SEK | -24.436% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 42.28% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -236.965% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 58.521% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 88.937% |
| CombiGene AB (publ) | 4.15 Million SEK | -91.266% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 88.823% |
| Intervacc AB (publ) | 21.68 Million SEK | 63.335% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 92.543% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 77.028% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 70.237% |
| Corline Biomedical AB | 6.78 Million SEK | -17.086% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 87.045% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 50.679% |
| Aptahem AB (publ) | 8.99 Million SEK | 11.656% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 82.787% |
| Fluicell AB (publ) | 8.91 Million SEK | 10.836% |
| Biovica International AB (publ) | 34.76 Million SEK | 77.136% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 31.874% |
| Abliva AB (publ) | 16.78 Million SEK | 52.631% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 96.296% |
| 2cureX AB (publ) | 2.93 Million SEK | -170.835% |
| I-Tech AB | 16.2 Million SEK | 50.947% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.33% |
| Cyxone AB (publ) | 4.69 Million SEK | -69.344% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 40.359% |
| Biosergen AB | 5.08 Million SEK | -56.323% |
| Nanologica AB (publ) | 79.32 Million SEK | 89.979% |
| SynAct Pharma AB | 51.83 Million SEK | 84.665% |
| BioInvent International AB (publ) | 90.45 Million SEK | 91.212% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -53.014% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 95.623% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -343.088% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 37.626% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -9.49% |